Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
Gregory M Pastores, Suma P Shankar, Milan Petakov, Pilar Giraldo, Hanna Rosenbaum, Dominick J Amato, Jeffrey Szer, Raul Chertkoff, Einat Brill-Almon, Ari Zimran, Gregory M Pastores, Suma P Shankar, Milan Petakov, Pilar Giraldo, Hanna Rosenbaum, Dominick J Amato, Jeffrey Szer, Raul Chertkoff, Einat Brill-Almon, Ari Zimran
Abstract
Taliglucerase alfa is the first available plant cell-expressed human recombinant therapeutic protein. It is indicated for treatment of patients with type 1 Gaucher disease (GD) in adult and pediatric patients in several countries. Study PB-06-002 examined the safety and efficacy of taliglucerase alfa for 9 months in patients who previously received imiglucerase. The results of adult patients from Study PB-06-002 who continued receiving taliglucerase alfa in extension Study PB-06-003 for up to 36 months are reported here. Eighteen patients received at least one dose of taliglucerase alfa in Study PB-06-003; 10 patients completed 36 total months of therapy, and four patients who transitioned to commercial drug completed 30-33 months of treatment. In patients who completed 36 total months of treatment, mean percent (±standard error) changes from baseline/time of switch to taliglucerase alfa to 36 months were as follows: hemoglobin concentration, -1.0% (±1.9%; n = 10); platelet count, +9.3% (±9.8%; n = 10); spleen volume measured in multiples of normal (MN), -19.8% (±9.9%; n = 7); liver volume measured in MN, +0.9% (±5.4%; n = 8); chitotriosidase activity, -51.5% (±8.1%; n = 10); and CCL18 concentration, -36.5 (±8.0%; n = 10). Four patients developed antidrug antibodies, including one with evidence of neutralizing activity in vitro. All treatment-related adverse events were mild or moderate and transient. The 36-month results of switching from imiglucerase to taliglucerase alfa treatment in adults with GD provide further data on the clinical safety and efficacy of taliglucerase alfa beyond the initial 9 months of the original study. www.clinicaltrials.gov identifier NCT00705939. Am. J. Hematol. 91:661-665, 2016. © 2016 Wiley Periodicals, Inc.
© 2016 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.
Figures
References
- Grabowski GA, Petsko GA, Kolodny EH. Gaucher disease In: Valle D, Beaudet AL, Vogelstein B, et al., editors. The Online Metabolic and Molecular Basis of Inherited Disease. New York, NY: The McGraw Hill Companies, Inc; 2010. Chapter 146.
- Grabowski GA, Kolodny EH, Weinreb NJ, et al. Gaucher disease: Phenotypic and genetic variation In: Valle D, Beaudet AL, Vogelstein B, et al., editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: The McGraw Hill Companies, Inc; 2010. Chapter 146.1.
- Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency―macrophage‐targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464–1470.
- Hollak CE, vom Dahl S, Aerts JM, et al. Force majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010;44:41–47.
- Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: A history and perspective. Drug Des Dev Ther 2012;6:81–106.
- Fox JL. First plant‐made biologic approved. Nat Biotechnol 2012;30:472.
- Grabowski GA, Golembo M, Shaaltiel Y. Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology. Mol Genet Metab 2014;112:1–8.
- National Institutes of Health. Switchover trial from imiglucerase to plant cell expressed recombinant human glucocerebrosidase [NCT00712348]. June 10, 2013; Available at: . Accessed: January 27, 2015.
- Pastores GM, Petakov M, Giraldo P, et al. A phase 3, multicenter, open‐label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis 2014;53:253–260.
- National Institutes of Health. Plant cell expressed recombinant human glucocerebrosidase extension trial [NCT00705939]. August 13, 2013; Available at: . Accessed: October 8, 2015.
- Zimran A, Brill‐Almon E, Chertkoff R, et al. Pivotal trial with plant cell‐expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011;118:5767–5773.
- Bracoud L, Ahmad H, Brill‐Almon E, Chertkoff R. Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model. Blood Cells Mol Dis 2011;46:47–52.
- Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:4–14.
- Elelyso [package insert]. New York, NY: Pfizer Labs; 2015.
Source: PubMed